Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96BD5
UPID:
PF21A_HUMAN
Alternative names:
BHC80a; BRAF35-HDAC complex protein BHC80
Alternative UPACC:
Q96BD5; D3DQP5; Q6AWA2; Q9C0G7; Q9H8V9; Q9HAK6; Q9NZE9
Background:
PHD finger protein 21A, also known as BHC80a and BRAF35-HDAC complex protein BHC80, plays a crucial role in the BHC complex, a corepressor mechanism that regulates transcription of neuron-specific genes in non-neuronal cells. It functions by modifying chromatin through deacetylation and demethylation, acting as a scaffold within the BHC complex and regulating demethylation processes.
Therapeutic significance:
The protein is implicated in Intellectual developmental disorder with behavioral abnormalities and craniofacial dysmorphism with or without seizures, a condition stemming from gene variants. Understanding PHD finger protein 21A's role could unveil new therapeutic strategies for this disorder.